Pancreatic Cancer Research

ResearcherTokushima UniversityActive in the last 2 years

Tetsuya Ikemoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9800-1359; OpenAlex author ID A5058026310. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  2. Outcomes of remnant pancreatic resection for recurrent pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4026151/v1↗
  3. Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02205-6↗
  4. Value of the CRP-albumin ratio in patients with resectable pancreatic cancer. Co-author DOI 10.2152/jmi.68.244↗
  5. Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer. Co-author DOI 10.2152/jmi.68.342↗
  6. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Co-author DOI 10.1111/cas.14527↗
  7. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  8. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  9. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10147-013-0529-6↗
  10. Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines. Co-author PMID 24982347↗
  11. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Co-author DOI 10.1007/s10147-011-0246-y↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuo Shimada · 10 shared papers, 2011–2024 · strength 0.94
  2. Yu Saito · 6 shared papers, 2011–2024 · strength 0.70
  3. Shinichiro Yamada · 3 shared papers, 2021–2024 · strength 0.50
  4. Yusuke Arakawa · 2 shared papers, 2021 · strength 0.27
  5. Hiroki Teraoku · 1 shared paper, 2024 · strength 0.23
  6. Takayuki Noma · 1 shared paper, 2024 · strength 0.23
  7. Yosuke Inoue · 1 shared paper, 2025 · strength 0.17
  8. So Yamaki · 1 shared paper, 2025 · strength 0.17
  9. Sohei Satoi · 1 shared paper, 2025 · strength 0.17
  10. Yuki Homma · 1 shared paper, 2025 · strength 0.17
  11. Yasunari Kawabata · 1 shared paper, 2025 · strength 0.17
  12. Katsuhisa Hirano · 1 shared paper, 2025 · strength 0.17
  13. Joji Kitayama · 1 shared paper, 2025 · strength 0.17
  14. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.17
  15. Toshimichi Asano · 1 shared paper, 2025 · strength 0.17
  16. Atsushi Oba · 1 shared paper, 2025 · strength 0.17
  17. Yasutoshi Kimura · 1 shared paper, 2025 · strength 0.17
  18. Daisuke Hashimoto · 1 shared paper, 2025 · strength 0.17
  19. Tomohisa Yamamoto · 1 shared paper, 2025 · strength 0.17
  20. Yuko Mataki · 1 shared paper, 2025 · strength 0.17
  21. Hiromitsu Maehira · 1 shared paper, 2025 · strength 0.17
  22. Ippei Matsumoto · 1 shared paper, 2025 · strength 0.17
  23. Makoto Yoshida · 1 shared paper, 2025 · strength 0.17
  24. Yasuhiro Kodera · 1 shared paper, 2025 · strength 0.17
  25. Michiaki Unno · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.